Novartis’ heart failure drug Entresto can be initiated early in hospitalized patients
August 26, 2018 No Comment
Swiss drugmaker Novartis unveiled new data on Entresto (sacubitril/valsartan) from a phase 4 study which confirms that the heart failure drug can be initiated early and safely across a broad range of heart failure patients with reduced ejection fraction (HFrEF), whose condition has been stabilized following hospitalization because of an acute heart failure episode. In […]
Continue reading …
Hyrimoz EC approval : Novartis’ Sandoz has bagged approval for Hyrimoz (adalimumab), a biosimilar of AbbVie’s Humira (adalimumab), in Europe for all indications of the reference drug including rheumatoid arthritis, Crohn’s disease, plaque psoriasis, uveitis and ulcerative colitis. The approval of Hyrimoz by European Commission (EC) was driven by analytical, preclinical and clinical research that […]
Continue reading …Novartis to in-license atopic dermatitis drug MOR106 from MorphoSys, Galapagos
July 21, 2018 No Comment
Novartis has agreed to acquire the exclusive global development and marketing rights of atopic dermatitis drug MOR106 from MorphoSys and Galapagos in a deal that could go up to $1.1 billion. The Swiss drugmaker will make an upfront payment of €95 million ($111 million) to Galapagos and MorphoSys apart from potential milestone payments of up […]
Continue reading …
Swiss pharma Novartis has announced that its lung cancer drug Zykadia (ceritinib) has been granted the FDA priority review for its expanded use as the first-line treatment for lung cancer patients with certain conditions. The expanded use is for metastatic non-small cell lung cancer (NSCLC) patients whose tumors were detected by an approved FDA test […]
Continue reading …
Business News Today
- German supermarket chain Lidl opens 800th UK store at Dumbarton, Scotland
- Jason Industries acquires Matchless Metal Polish Company
- Takeda Pharmaceutical acquires celiac disease drug developer PvP Biologics
- Pet Plate raises $9m funding to expand pet food subscription service
- Nationwide, Generali to create N2G Worldwide Insurance Services JV
- Manna Tree Partners invests in organic beef producer Verde Farms
- Pernod Ricard rolls out caviar-infused vodka – L’Orbe Vodka x Caviar
- Skogul oil field : Aker BP set to begin production from Norwegian oil field
- COSMIC-311 clinical trial : Exelixis enrolls patients to study cabozantinib in phase 3 thyroid cancer trial
- Cystic fibrosis drug KALYDECO to be launched in New Zealand by Vertex Pharmaceuticals
